Vardenafil

Vardenafil is a synthetic small-molecule drug that inhibits the enzyme phosphodiesterase type 5 (PDE5), placing it in the same therapeutic class as sildenafil and tadalafil ^[1]. Its structure closely resembles that of sildenafil, differing at only a couple of positions, and among the marketed PDE5 inhibitors it is one of the most potent at its target enzyme ^[1]. It is taken by mouth and is available as conventional tablets and as an orally disintegrating tablet ^[2].

Its established medical use is the treatment of erectile dysfunction, where it helps men obtain and keep an erection sufficient for sexual activity in response to arousal ^[2]. Controlled trials using objective measures such as stopwatch-timed duration of erection have confirmed that it improves erectile function and related aspects of sexual quality of life compared with placebo ^[2]. It has also been studied for premature ejaculation, where taking it on demand lengthened the time to ejaculation in some men ^[3].

Vardenafil was developed by Bayer and co-marketed with partners including GlaxoSmithKline and Schering-Plough, reaching the market in the early 2000s under the brand name Levitra; an orally disintegrating version is sold as Staxyn, and the drug has appeared under other names such as Vivanza in some countries ^[1][2]. Regulatory rights and co-promotion arrangements shifted between the companies over the following years.

Vardenafil is a prescription-only medicine. Common side effects are generally mild and include headache, facial flushing, nasal congestion and indigestion ^[3]. Its use is contraindicated together with nitrate medications, because the combination can cause a dangerous fall in blood pressure, and caution is advised with certain drugs that prolong the heart's QT interval ^[1]. Regulators have also noted rare reports of sudden hearing loss with PDE5 inhibitors as a class. Because vardenafil and related drugs are sometimes found as hidden adulterants in products sold as herbal or natural sexual enhancers, authorities have warned that such unlabeled products can carry undisclosed health risks.

Vardenafil is prescription only. Typical effects are headache, facial flushing, stuffy nose, and indigestion, all from vessel widening elsewhere in the body. The critical rule is that it must never be combined with nitrate heart medicines or the recreational nitrites called poppers, since the two together can cause a life-threatening drop in blood pressure. It should be used carefully with alpha-blockers for the same reason. It can modestly prolong the heart's QT interval, so it is avoided with certain antiarrhythmics. Any erection lasting over four hours, called priapism, is an emergency. It is processed by CYP3A4, so strong inhibitors of that enzyme raise its levels.

Vardenafil is absolutely contraindicated with organic nitrates due to a severe pharmacodynamic interaction; concurrent use produces dangerous synergistic vasodilation and hypotension that can result in cardiovascular collapse ^{[5] [6]}. This is the most significant documented interaction. Vardenafil is also not recommended with type 1A antiarrhythmics (quinidine, procainamide) or type III antiarrhythmics (amiodarone, sotalol) due to potential cardiac rhythm disturbances, though the mechanism is incompletely characterized ^[7].

The drug undergoes CYP3A4 metabolism, so potent CYP3A4 inhibitors including azole antifungals, macrolide antibiotics, and antiretroviral protease inhibitors increase vardenafil plasma concentrations and adverse effect risk by reducing clearance; this is a pharmacokinetic interaction ^[7]. Alpha-blocker coadministration is now considered a precaution rather than an absolute contraindication based on recent evidence. Statins and testosterone appear to have synergistic beneficial effects with vardenafil. Many common medications have not been formally studied with vardenafil, particularly those metabolized by pathways other than CYP3A4.

Checking a whole stack? Run it through interactions + stacks.

Vardenafil is a phosphodiesterase type 5 inhibitor developed by Bayer and brought to market in collaboration with GlaxoSmithKline as part of the second wave of oral erectile dysfunction treatments that followed sildenafil. It was approved by the United States Food and Drug Administration in 2003 and sold under the brand name Levitra, offering an alternative within the same drug family as sildenafil and tadalafil.

The molecule is highly selective for PDE5, the enzyme that degrades cyclic GMP in the smooth muscle of the penis, and it was noted for its potency at that target. In 2010 an orally disintegrating formulation designed to dissolve on the tongue was introduced under the name Staxyn, providing a more discreet dosing option. Like others in its class, vardenafil supports rather than initiates an erection, since it works by amplifying the body's natural nitric-oxide response to sexual stimulation.

Vardenafil is well regarded as an effective and reliable treatment for erectile dysfunction, holding a firm place alongside sildenafil and tadalafil in clinical practice guidelines. It is often noted for its high selectivity and potency against PDE5, and many men and clinicians consider it a dependable on-demand option. European and international urology guidelines endorse the PDE5 inhibitor class, including vardenafil, as first-line pharmacotherapy with high efficacy and safety rates, even in populations that can be difficult to treat, such as men with diabetes.

Its availability as an orally disintegrating tablet adds a measure of convenience and discretion that some users prefer. As with all drugs in this class, it must not be combined with nitrates, and occasional visual effects can occur because of minor activity at the retinal enzyme PDE6; within appropriate use, however, vardenafil is a trusted and well-established therapy.